Skip to content
MMR Sign In Subscribe

Aurobindo gets FDA approval for amoxicillin and clavulanate potassium for oral suspension

Aurobindo has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for amoxicillin and clavulanate potassium for oral suspension USP, 125 mg/31.25 mg per 5 mL and 250 mg/62.5 mg per 5 mL.

,   and  CDR
1 min read

Table of Contents

EAST WINDSOR, N.J. — Aurobindo has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for amoxicillin and clavulanate potassium for oral suspension USP, 125 mg/31.25 mg per 5 mL and 250 mg/62.5 mg per 5 mL. Aurobindo’s amoxicillin and clavulanate potassium for oral suspension is an AB-rated

generic equivalent to the reference listed drug, Neopharma’s Augmentin.

Amoxicillin and clavulanate potassium for oral suspension USP is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for treatment of the following:

  • Lower respiratory tract infections
  • Acute bacterial otitis media
  • Sinusitis
  • Skin and skin structure infections
  • Urinary tract infections

Comments

Latest